Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Bakris GL, et al. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081. JAMA. 2015. PMID: 26325557 Clinical Trial.
The effect of liraglutide on renal function: A randomized clinical trial.
von Scholten BJ, Persson F, Rosenlund S, Hovind P, Faber J, Hansen TW, Rossing P. von Scholten BJ, et al. Among authors: faber j. Diabetes Obes Metab. 2017 Feb;19(2):239-247. doi: 10.1111/dom.12808. Epub 2016 Nov 21. Diabetes Obes Metab. 2017. PMID: 27753201 Clinical Trial.
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
von Scholten BJ, Persson F, Rosenlund S, Eugen-Olsen J, Pielak T, Faber J, Hansen TW, Rossing P. von Scholten BJ, et al. Among authors: faber j. Diabetes Obes Metab. 2017 Jun;19(6):901-905. doi: 10.1111/dom.12884. Epub 2017 Mar 2. Diabetes Obes Metab. 2017. PMID: 28105731 Clinical Trial.
Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
Jürgens M, Schou M, Hasbak P, Kjær A, Wolsk E, Zerahn B, Wiberg M, Brandt NH, Gæde PH, Rossing P, Faber J, Inzucchi S, Gustafsson F, Kistorp CM. Jürgens M, et al. Among authors: faber j. BMJ Open. 2019 Nov 27;9(11):e029098. doi: 10.1136/bmjopen-2019-029098. BMJ Open. 2019. PMID: 31780586 Free PMC article.
Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial.
Eickhoff MK, Olsen FJ, Frimodt-Møller M, Diaz LJ, Faber J, Jensen MT, Rossing P, Persson F. Eickhoff MK, et al. Among authors: faber j. J Diabetes Complications. 2020 Jul;34(7):107590. doi: 10.1016/j.jdiacomp.2020.107590. Epub 2020 Apr 18. J Diabetes Complications. 2020. PMID: 32340841 Clinical Trial.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.
Jürgens M, Schou M, Hasbak P, Kjær A, Wolsk E, Zerahn B, Wiberg M, Brandt-Jacobsen NH, Gæde P, Rossing P, Faber J, Inzucchi SE, Gustafsson F, Kistorp C. Jürgens M, et al. Among authors: faber j. J Am Heart Assoc. 2021 Aug 3;10(15):e020418. doi: 10.1161/JAHA.120.020418. Epub 2021 Jul 19. J Am Heart Assoc. 2021. PMID: 34278803 Free PMC article. Clinical Trial.
1,340 results